

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

Phospho-ALK (Tyr1604) Antibody

RRID:AB_331047

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3341, RRID:AB_331047

Antibody Information

URL: http://antibodyregistry.org/AB_331047

Proper Citation: Cell Signaling Technology Cat# 3341, RRID:AB_331047

Target Antigen: Phospho-ALK (Tyr1604)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10078902, AB_10078903, AB_331047, AB_331048.

Antibody Name: Phospho-ALK (Tyr1604) Antibody

Description: This polyclonal targets Phospho-ALK (Tyr1604)

Target Organism: h, human

Antibody ID: AB_331047

Vendor: Cell Signaling Technology

Catalog Number: 3341

Record Creation Time: 20231110T081400+0000

Record Last Update: 20260901T035702+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-ALK (Tyr1604) Antibody.

No alerts have been found for Phospho-ALK (Tyr1604) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hang JF, et al. (2026) Out-of-frame CBX3::ALK fusion drives ALK activation and therapy response. Cell reports. Medicine, 7(4), 102697.

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. Molecular cancer therapeutics, 24(9), 1389.

Pattabiraman N, et al. (2025) A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma. Cancers, 17(20).

Dedoni S, et al. (2024) Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase. Biomolecules, 14(6).

Li X, et al. (2024) A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance. iScience, 27(2), 109015.

Bergaggio E, et al. (2023) ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer cell, 41(12), 2100.

Huang Q, et al. (2023) DAB2IP suppresses invadopodia formation through destabilizing ALK by interacting with USP10 in breast cancer. iScience, 26(9), 107606.

Tulpule A, et al. (2021) Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell, 184(10), 2649.

Huang H, et al. (2021) Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell reports, 36(2), 109363.

Inam H, et al. (2021) Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors. iScience, 24(11), 103343.

Cohen MA, et al. (2020) Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cell stem cell, 26(4), 579.

Siaw JT, et al. (2020) 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Cell reports, 32(12), 108171.